Teva Regrets Canning Worker With Brain Tumor
May 7th, 2013 // 12:55 pm @ jmpickett
Updated Daily – Read our latest FDA, cGMP Compliance News
Teva Pharmaceuticals is one of the major employers in Israel, and it is deciding to not battle a recent court ruling that left the drug company looking heartless.
A district labor court judge in Tel Aviv told Teva to pay about $600,000, plus court costs, to the estate of an ex-employee who was an assistant to the CEO and President of the company. She was fired because she was diagnosed with a serious brain tumor.
- May 22 – Avoiding Warning Letter Disasters With a Strong cGMP and GCP Quality Agreement
- May 22 – Avoid the CDRH eCopy Confusion – How to Prepare a Compliant eCopy Submission
In the ruling, the judge blasted Teva, saying that the society of Israel saw a very dismal picture, and it is very wrong for a company in a civilized nation to do such a thing, especially because Teva is a public company. This behavior is out of character for Teva, which is well known for contributing to the local economy and also to the society of Israel.
Teva argued that it had acted appropriately towards the employee and went well beyond what the law requires, both personally and financially. The company also noted that complaints at work had been lodged against the worker.
But the new CEO, Jeremy Levin, is not pleased with what happened in this case. This week he wrote to employees that he regrets the conduct in this situation by Teva, and the insensitivity and lack of common sense in this case. He stressed in his letter that this sort of thing should not happen and it goes against the values of Teva.
Upcoming FDA cGMP Expertbriefings.com Webinars for 2013 include:
- May 13 – Breaking Regulatory Update for Life Science Firms – UFA Requirements for eCTDs
- May 14 – How to Effectively Source OTC, Generics and APIs from Indian Pharma Manufacturers
- May 14 – How to Survive PREDICT – FDA’s New Import Screening Program
- May 15 – FDA Chief Counsel Report – How to Deal With and Avoid Warning Letters
- May 16 – Spend $500K on Compliance or $300 Million on Consent Decree? – Essential cGMP Compliance Tips for Sr. Management
- May 22 – FDA Recall Chief Update – How to Design a Bulletproof Recall Strategy
- May 22 – Avoiding Warning Letter Disasters With a Strong cGMP and GCP Quality Agreement
- May 22 – Avoid the CDRH eCopy Confusion – How to Prepare a Compliant eCopy Submission
- May 30 – The Essentials of Complaint Handling and Post Market Management – How to Comply With Global Regulatory Requirements
- May 30 – Audit Your Lab Like an FDA Auditor – A Roadmap to cGMP Lab Compliance
- June 4Â -Â How to Prepare Yourself for 21 CFR Part 11 Inspections
